Milestone Pharma provides corporate presentation ahead of March 27 PDUFA for CARDAMYST

Milestone Pharmaceuticals Inc.

NDA for CARDAMYST (etripamil) nasal spray remains under FDA review with PDUFA date of March 27, 2025.
Presentation outlines potential commercial launch strategy, but product is not yet approved.
Company actively preparing for launch pending FDA decision.
Presentation used at investor meetings; available on company website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.